Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers
Lonza Group Ltd. (SWX: LONN) and Antharis Therapeutics announced on June 15, 2026, an exclusive,...
Lonza Group Ltd. (SWX: LONN) and Antharis Therapeutics announced on June 15, 2026, an exclusive,...
German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from...
Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a...